NEW YORK, NY / ACCESSWIRE / February 6, 2018 / The markets recent selloff continued Monday as a result of rising interest rates. Both the Dow Jones and the S&P 500 fell sharply to close in negative territory year-to-date. The Dow Jones Industrial Average dropped 4.60 percent to close at 24,345.75, down 1.51 percent year-to-date, while the S&P 500 Index fell 4.10 percent, the biggest one day drop for the index in six years, to close at 2,648.94, down 0.92 percent year-to-date. All of the sectors in the S&P 500 and the 30 members of the Dow closed in the red on Monday.

"We're not used to getting washouts like this anymore," said Quincy Krosby, chief market strategist at Prudential Financial, according to CNBC. "The buy-the-dip mentality that has taken over hasn't allowed for that."

"This sell-off, in the bigger scheme of things, is not that big. But it is very important in psychological terms," Krosby said.

RDI Initiates Coverage on:

Sarepta Therapeutics, Inc.
https://rdinvesting.com/news/?ticker=SRPT

Valeant Pharmaceuticals Intl Inc.
https://rdinvesting.com/news/?ticker=VRX

Sarepta Therapeutics? stock moved 3.99% lower Monday, to close the day at $60.60. The stock recorded a trading volume of 1,736,491 shares, which was above its three months average volume of 1,700,224 shares. In the last year, Sarepta Therapeutics? shares have traded in a range of 26.26 - 68.90. The share price has gained 130.77% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $60.16 is greater than its 200-day moving average of $50.11. Shares of Sarepta Therapeutics have gained roughly 10.44 percent in the past month and are up 8.91 percent year-to-date.

Access RDI?s Sarepta Therapeutics, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=SRPT

On Monday, shares of Valeant Pharmaceuticals recorded a trading volume of 14,742,745 shares, which was below the three months average volume of 19,100,360 shares. The stock ended the day 4.00% lower at 17.28. The share price has gained 107.94% from its 52 week low with a 52 week trading range of 8.31 - 24.43. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $21.46 is greater than its 200-day moving average of $16.38. Shares of Valeant Pharmaceuticals are trading at a trailing Price to Earnings ratio of 4.41. Shares of Valeant Pharmaceuticals have fallen roughly 27.55 percent in the past month and are down 16.84 percent year-to-date.

Access RDI?s Valeant Pharmaceuticals Intl Inc. Research Report at:
https://rdinvesting.com/news/?ticker=VRX

Our Actionable Research on Sarepta Therapeutics, Inc. (NASDAQ:SRPT) and Valeant Pharmaceuticals Intl Inc. (NYSE:VRX) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com